Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Krystal Biotech, Inc.
  6. News
  7. Summary
    KRYS   US5011471027

KRYSTAL BIOTECH, INC.

(KRYS)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-06 pm EST
79.95 USD   -0.32%
01/19Insider Sell: Krystal Biotech
MT
01/18Krystal Biotech Says European Commission's Orphan Designation Received for Cystic Fibrosis Treatment Candidate
MT
01/18Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : Krystal Biotech, Inc. Presents at Bank of America 2022 Virtual Biotech SMID Cap Conference, Dec-07-2022 02:20 PM

12/07/2022 | 02:20pm EST
share with twitter
share with LinkedIn
share with facebook
All right. Great. Hey, everyone. Good afternoon, and welcome to day 1 of the 2022 Bank of America's mid Biotech Conference. Thanks for joining the session with Krystal Biotech. My name is Alec...


© S&P Capital IQ 2022
All news about KRYSTAL BIOTECH, INC.
01/19Insider Sell: Krystal Biotech
MT
01/18Krystal Biotech Says European Commission's Orphan Designation Received for Cystic Fibro..
MT
01/18Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treat..
AQ
01/09Krystal Biotech, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
01/09Krystal Biotech Announces FDA's 3-Month Extension of BLA PDUFA Date and Regulatory Upda..
AQ
01/09Krystal Biotech, Inc. Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regu..
CI
01/04Insider Sell: Krystal Biotech
MT
01/04Insider Sell: Krystal Biotech
MT
2022Insider Sell: Krystal Biotech
MT
2022Insider Sell: Krystal Biotech
MT
More news
Analyst Recommendations on KRYSTAL BIOTECH, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -142 M - -
Net cash 2022 368 M - -
P/E ratio 2022 -14,4x
Yield 2022 -
Capitalization 2 059 M 2 059 M -
EV / Sales 2022 -
EV / Sales 2023 38,5x
Nbr of Employees 119
Free-Float 79,9%
Chart KRYSTAL BIOTECH, INC.
Duration : Period :
Krystal Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KRYSTAL BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 79,95 $
Average target price 107,25 $
Spread / Average Target 34,1%
EPS Revisions
Managers and Directors
Krish S. Krishnan Chairman, President & Chief Executive Officer
Suma M. Krishnan Director, President-Research & Development
George Chen Manager-Information Technology & CSV
Trevor Parry Senior Director-Scientific Affairs
Brittani Agostini Senior Manager-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
KRYSTAL BIOTECH, INC.0.92%2 059
REGENERON PHARMACEUTICALS, INC.8.54%83 640
VERTEX PHARMACEUTICALS4.24%77 269
WUXI APPTEC CO., LTD.12.89%40 679
BIONTECH SE-5.43%34 523
BEIGENE, LTD.16.80%26 752